Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter reports strong second-quarter growth

Baxter reports strong second-quarter growth

23rd July 2012

Baxter has published its second quarter financial report for 2012, during which it experienced year-on-year business growth of seven percent.

The company generated $661 million (426.71 million pounds) in income during the three-month period, up from $615 million during Q2 2011, which contributed to a nine percent annual growth rate for the first half of the year.

Meanwhile, global sales rose by one percent to $3.6 billion, with strong demand for haemophilia treatment Advate, plasma-based therapeutics and surgical sealants all cited as contributing factors.

The acquisition and integration of Synovis Life Technologies in Q1 2012 also bolstered performance, thus keeping Baxter on track to meet its fiscal targets for the year.

Robert Parkinson Jr, chairman and chief executive officer at Baxter, said: "We remain confident that the focus on our diversified portfolio of critical therapies and innovation will position us well for future growth."

Last week, the company announced a new collaboration with Stichting Sanquin Bloedvoorziening that will allow it to further expand its ability to deliver plasma-derived treatments.ADNFCR-8000103-ID-801413209-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.